FDA approves Perjeta for neoadjuvant breast cancer treatment

FDA approves Perjeta for neoadjuvant breast cancer treatment

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved

5
Like
Save

Comments

Write a comment

*